Sangamo enters into asset sale agreements with Lilly and Astellas

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Poster: ST-506 mediates brainwide lowering of prion protein in nonhuman primates via a conserved blood-brain-barrier crossing mechanism, as a potential one-time treatment for prion disease

Download PDF